PNC Financial Services Group’s Celgene Corporation Contingent Value Rights CELGZ Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q4
Sell
-68
Closed 4243
2019
Q3
$0 Hold
68
﹤0.01% 4245
2019
Q2
$0 Hold
68
﹤0.01% 4283
2019
Q1
$0 Hold
68
﹤0.01% 4281
2018
Q4
$0 Hold
68
﹤0.01% 4343
2018
Q3
$0 Hold
68
﹤0.01% 4383
2018
Q2
$0 Hold
68
﹤0.01% 4413
2018
Q1
$0 Sell
68
-20
-23% -$13 ﹤0.01% 4409
2017
Q4
$0 Buy
88
+20
+29% +$23 ﹤0.01% 4388
2017
Q3
$0 Hold
68
﹤0.01% 4373
2017
Q2
$0 Hold
68
﹤0.01% 4341
2017
Q1
$0 Hold
68
﹤0.01% 4336
2016
Q4
$0 Hold
68
﹤0.01% 4233
2016
Q3
$0 Hold
68
﹤0.01% 4644
2016
Q2
$0 Sell
68
-600
-90% -$773 ﹤0.01% 4701
2016
Q1
$0 Buy
668
+600
+882% +$803 ﹤0.01% 4722
2015
Q4
$0 Hold
68
﹤0.01% 4774
2015
Q3
$0 Hold
68
﹤0.01% 4874
2015
Q2
$0 Hold
68
﹤0.01% 4908
2015
Q1
$0 Hold
68
﹤0.01% 4893
2014
Q4
$0 Hold
68
﹤0.01% 4406
2014
Q3
$0 Hold
68
﹤0.01% 4143
2014
Q2
$0 Hold
68
﹤0.01% 4017
2014
Q1
$0 Hold
68
﹤0.01% 3998
2013
Q4
$0 Hold
68
﹤0.01% 3833
2013
Q3
$0 Buy
+68
New +$524 ﹤0.01% 3751

PNC Financial Services Group's CELGZ Position: Q4 2019 in Review

PNC Financial Services Group sold out of Celgene Corporation Contingent Value Rights (CELGZ) in Q4 2019, closing a stake of 68 shares.

PNC Financial Services Group first reported a position in CELGZ in Q3 2013 and held it in 25 quarters. The position peaked at $0 in Q3 2019. 0 funds tracked by Wall St. Rank hold CELGZ as of Q4 2019.

  • PNC Financial Services Group reported no remaining Celgene Corporation Contingent Value Rights position as of Q4 2019 after selling out during the quarter.
  • PNC Financial Services Group sold 68 Celgene Corporation Contingent Value Rights shares in Q4 2019.
  • PNC Financial Services Group first reported a position in Celgene Corporation Contingent Value Rights in Q3 2013 and held it in 25 quarters.
  • PNC Financial Services Group's Celgene Corporation Contingent Value Rights position peaked at $0 in Q3 2019.
  • 0 funds tracked by Wall St. Rank held Celgene Corporation Contingent Value Rights as of Q4 2019.

Based on PNC Financial Services Group's 13F filing for Q4 2019, filed 7 Feb 2020.